December 21
Eligard� Gains Approvals in 24 European Countries
PDF version
December 15
FDA Approves Eligard� Six-Month Formulation for Prostate Cancer
December 8
QLT Hosts 2004 Analyst & Investor Meeting and Webcast
November 19
QLT and Atrix Laboratories Complete Merger
October 21
QLT Announces Q3 Results for 2004
October 14
QLT And Atrix Laboratories Joint Proxy Statement Cleared By SEC
Visudyne� in Occult (VIO) Trial to Continue to its Conclusion at 24 Months
August 30
QLT Reiterates Confidence in Visudyne's Potential
July 22
QLT Announces Q2 Results for 2004
July 20
QLT Announces Visudyne� Sales for Second Quarter of 2004
July 13
QLT Inc. and Atrix Laboratories, Inc. Announce Early Termination of Hart-Scott-Rodino Waiting Period
June 14
QLT Inc. and Atrix Laboratories Inc. Combine to Create Leading Profitable
Biopharmaceutical Company
June 2
QLT Collaborates With the National Eye Institute to Develop Preservative-Free Triamcinolone
April 27
QLT Announces Q1 Results for 2004 and Updates Guidance
April 23
QLT Announces Reimbursement for Visudyne� in Japan for Treatment of Age-Related Macular Degeneration
April 22
QLT Announces Visudyne� Sales for First Quarter of 2004
April 2
QLT Announces Securities Class Action Lawsuit Is Dismissed
April 1
QLT Announces New Medicare Policy Takes Effect Expanding Reimbursement for Visudyne�
March 29
QLT to Acquire Kinetek Pharmaceuticals Inc.
March 16
QLT Announces Visudyne� to Receive Centers for Medicare and Medicaid Exception on Allowable Reimbursement Level
February 11
QLT Reports 2003 Fourth Quarter and Full Year Earnings Per Share of $0.13 and $0.65 and Provides Guidance for 2004
January 29
QLT and Novartis Announce Centers for Medicare and Medicaid Services Intend to Reimburse Visudyne� for Occult and Minimally Classic Lesions in AMD
January 23
QLT Announces Effectiveness of its Registration Statement on Form S-3 for its August 2003 Private Placement of Convertible Notes
January 22
QLT Announces Visudyne� Sales for Fourth Quarter and Fiscal Year 2003
January 19
QLT Announces Discount to Physician Customers in Response to the Reduction in Medicare Reimbursement for Visudyne�
